A PHASE I AND EXPANSION COHORT STUDY OF ADJUVANT CISPLATIN INTENSITY-MODULATED RADIOTHERAPY AND MK-3475 (PEMBROLIZUMAB) IN HIGH-RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Brief description of study
If you have been diagnosed with Human Papillomavirus (HPV)-negative head and neck cancer, you may qualify for this Phase I study investigating the drug pembrolizumab. The main goal of this study is to test the safety and schedule of adding full-dose pembrolizumab to radiation therapy and cisplatin chemotherapy.
Clinical Study Identifier: s17-00093
ClinicalTrials.gov Identifier: NCTs17-00093
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
